<p>Pacira BioSciences, Inc.（納斯達克代碼：PCRX - 獲取免費報告）首席財務官 Shawn Cross 於 12 月 10 日（星期三）出售了 9,104 股公司的股票。股票以平均價格 25.14 美元出售，總交易額為 228,874.56 美元。交易完成後，首席財務官在公司持有 56,250 股，價值 1,414,125 美元。這代表其持股減少了 13.93%。此次出售在向證券交易委員會的備案中披露，具體內容可通過此鏈接訪問。</p>
<p>Shawn Cross 最近還進行了以下交易：</p>
<ul>
<li>在 12 月 9 日（星期二），Shawn Cross 出售了 15,896 股 Pacira BioSciences 的股票。股票以平均價格 25.03 美元出售，總交易額為 397,876.88 美元。</li>
</ul>
<p>獲取 <strong>Pacira BioSciences</strong> 的提醒：</p>
<h2>Pacira BioSciences 股票表現</h2>
<p>納斯達克 PCRX 在星期四上漲 0.55 美元，達到 25.73 美元。該股票的交易量為 1,121,447 股，而其平均交易量為 639,245 股。Pacira BioSciences, Inc.的股價一年低點為 18.17 美元，一年高點為 27.64 美元。公司的 50 日移動平均線為 23.11 美元，200 日移動平均線為 24.15 美元。公司的速動比率為 3.78，流動比率為 5.26，債務股本比率為 0.52。該股票的市值為 11.1 億美元，市盈率為 57.18，貝塔值為 0.23。</p>
<p>Pacira BioSciences（納斯達克代碼：PCRX - 獲取免費報告）最近在 11 月 6 日（星期四）發佈了季度財報。公司報告本季度每股收益（EPS）為 0.70 美元，超出市場共識預期的 0.65 美元，超出 0.05 美元。Pacira BioSciences 的股本回報率為 12.82%，淨利潤率為 2.99%。本季度公司的收入為 1.7952 億美元，而分析師預期為 1.8286 億美元。去年同期，該公司每股收益為 0.79 美元。本季度的收入同比增長 6.5%。分析師平均預計 Pacira BioSciences, Inc.在當前年度的每股收益為 2.41 美元。</p>
<h2>對 Pacira BioSciences 的對沖基金看法</h2>
<p>對沖基金最近對該股票的持倉進行了調整。Natixis Advisors LLC 在第一季度購買了 Pacira BioSciences 的新頭寸，價值 327,000 美元。US Bancorp DE 在第一季度將其在 Pacira BioSciences 的持股增加了 31.0%。US Bancorp DE 現在持有 2,270 股公司股票，價值 56,000 美元，此前在上個季度購買了 537 股。Charles Schwab Investment Management Inc.在第一季度將其在 Pacira BioSciences 的股份增加了 4.4%。Charles Schwab Investment Management Inc.現在持有 524,486 股公司股票，價值 13,033,000 美元，此前在該期間購買了 22,282 股。Connor Clark &amp; Lunn Investment Management Ltd.在第一季度將其在 Pacira BioSciences 的股份增加了 288.3%。Connor Clark &amp; Lunn Investment Management Ltd.現在持有 171,377 股公司股票，價值 4,259,000 美元，此前在上個季度購買了 127,240 股。最後，Invesco Ltd.在第一季度將其在 Pacira BioSciences 的股份增加了 159.9%。Invesco Ltd.現在持有 624,865 股公司股票，價值 15,528,000 美元，此前在上個季度購買了 384,419 股。目前 99.73% 的股票由機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>PCRX 成為多份研究分析師報告的主題。HC Wainwright 在 11 月 17 日（星期一）的研究報告中重申了對 Pacira BioSciences 的 “買入” 評級，並設定了 38.00 美元的目標價。Zacks Research 在 8 月 14 日（星期四）的研究報告中將 Pacira BioSciences 的評級從 “強烈賣出” 上調至 “持有”。Wall Street Zen 在 11 月 8 日（星期六）的報告中將 Pacira BioSciences 的評級從 “買入” 上調至 “強烈買入”。Weiss Ratings 在週一的報告中重申了對 Pacira BioSciences 的 “賣出（d+）” 評級。最後，Truist Financial 在 11 月 7 日（星期五）的報告中將 Pacira BioSciences 的目標價從 30.00 美元下調至 28.00 美元，並對該公司設定了 “買入” 評級。三位研究分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，共識目標價為 28.20 美元。</p>
<p><strong>查看我們最新的 Pacira BioSciences 股票報告</strong></p>
<h2>Pacira BioSciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Pacira Biosciences, Inc.是一家控股公司，專注於提供非阿片類疼痛管理和再生健康解決方案，以改善患者在神經疼痛路徑上的體驗。其產品包括 EXPAREL、iovera 和 DepoFoam。該公司成立於 2006 年 12 月，總部位於佛羅里達州坦帕。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票比 Pacira BioSciences 更好</li>
<li>如何捕捉股息增加的好處</li>
<li>2026 年應避免的 3 只最近被下調評級的股票</li>
<li>異常交易量的股票：如何實時找到異常交易量的股票</li>
<li>芯片熱潮迴歸：3 只有巨大收益潛力的股票</li>
<li>交易暫停的解釋</li>
<li>甲骨文股票受重創：為何其 AI 管道可能推動 2026 年反彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Pacira BioSciences 嗎？</h2>
<p>在考慮 Pacira BioSciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Pacira BioSciences 並不在名單上。</p>
<p>雖然 Pacira BioSciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Pacira制藥

<p>Pacira 製藥首席財務官 Shawn Cross 以每股 25.14 美元的價格出售了 9,104 股，總計 228,874.56 美元，減少了 13.93% 的持股比例。該交易已在 SEC 文件中披露。股票的表現和最近的分析師評級也被討論，來自不同分析師的評級存在分歧</p>

<p>Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) CFO Shawn Cross sold 9,104 shares of the business's stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $25.14, for a total transaction of $228,874.56. Following the completion of the transaction, the chief financial officer owned 56,250 shares in the company, valued at $1,414,125. This represents a 13.93% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Pacira BioSciences, Inc.（納斯達克代碼：PCRX - 獲取免費報告）首席財務官 Shawn Cross 於 12 月 10 日（星期三）出售了 9,104 股公司的股票。股票以平均價格 25.14 美元出售，總交易額為 228,874.56 美元。交易完成後，首席財務官在公司持有 56,250 股，價值 1,414,125 美元。這代表其持股減少了 13.93%。此次出售在向證券交易委員會的備案中披露，具體內容可通過此鏈接訪問。</p>
</div><p>Shawn Cross also recently made the following trade(s):</p>
<div class="lb-trans"><p>Shawn Cross 最近還進行了以下交易：</p>
</div><ul>
<li>On Tuesday, December 9th, Shawn Cross sold 15,896 shares of Pacira BioSciences stock. The stock was sold at an average price of $25.03, for a total transaction of $397,876.88.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 9 日（星期二），Shawn Cross 出售了 15,896 股 Pacira BioSciences 的股票。股票以平均價格 25.03 美元出售，總交易額為 397,876.88 美元。</li>
</ul>
</div><p>Get <strong>Pacira BioSciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Pacira BioSciences</strong> 的提醒：</p>
</div><h2>Pacira BioSciences Stock Performance</h2>
<div class="lb-trans"><h2>Pacira BioSciences 股票表現</h2>
</div><p>NASDAQ PCRX traded up $0.55 on Thursday, hitting $25.73. The stock had a trading volume of 1,121,447 shares, compared to its average volume of 639,245. Pacira BioSciences, Inc. has a one year low of $18.17 and a one year high of $27.64. The company's 50-day moving average is $23.11 and its two-hundred day moving average is $24.15. The company has a quick ratio of 3.78, a current ratio of 5.26 and a debt-to-equity ratio of 0.52. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of 57.18 and a beta of 0.23.</p>
<div class="lb-trans"><p>納斯達克 PCRX 在星期四上漲 0.55 美元，達到 25.73 美元。該股票的交易量為 1,121,447 股，而其平均交易量為 639,245 股。Pacira BioSciences, Inc.的股價一年低點為 18.17 美元，一年高點為 27.64 美元。公司的 50 日移動平均線為 23.11 美元，200 日移動平均線為 24.15 美元。公司的速動比率為 3.78，流動比率為 5.26，債務股本比率為 0.52。該股票的市值為 11.1 億美元，市盈率為 57.18，貝塔值為 0.23。</p>
</div><p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.The company had revenue of $179.52 million for the quarter, compared to analysts' expectations of $182.86 million. During the same period last year, the firm earned $0.79 EPS. The firm's revenue for the quarter was up 6.5% on a year-over-year basis. On average, analysts expect that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.</p>
<div class="lb-trans"><p>Pacira BioSciences（納斯達克代碼：PCRX - 獲取免費報告）最近在 11 月 6 日（星期四）發佈了季度財報。公司報告本季度每股收益（EPS）為 0.70 美元，超出市場共識預期的 0.65 美元，超出 0.05 美元。Pacira BioSciences 的股本回報率為 12.82%，淨利潤率為 2.99%。本季度公司的收入為 1.7952 億美元，而分析師預期為 1.8286 億美元。去年同期，該公司每股收益為 0.79 美元。本季度的收入同比增長 6.5%。分析師平均預計 Pacira BioSciences, Inc.在當前年度的每股收益為 2.41 美元。</p>
</div><h2>Hedge Funds Weigh In On Pacira BioSciences</h2>
<div class="lb-trans"><h2>對 Pacira BioSciences 的對沖基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the stock. Natixis Advisors LLC purchased a new position in Pacira BioSciences in the first quarter worth $327,000. US Bancorp DE raised its holdings in Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company's stock worth $56,000 after purchasing an additional 537 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Pacira BioSciences by 4.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 524,486 shares of the company's stock worth $13,033,000 after purchasing an additional 22,282 shares during the period. Connor Clark &amp; Lunn Investment Management Ltd. increased its stake in shares of Pacira BioSciences by 288.3% during the first quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 171,377 shares of the company's stock valued at $4,259,000 after purchasing an additional 127,240 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Pacira BioSciences by 159.9% during the 1st quarter. Invesco Ltd. now owns 624,865 shares of the company's stock valued at $15,528,000 after purchasing an additional 384,419 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金最近對該股票的持倉進行了調整。Natixis Advisors LLC 在第一季度購買了 Pacira BioSciences 的新頭寸，價值 327,000 美元。US Bancorp DE 在第一季度將其在 Pacira BioSciences 的持股增加了 31.0%。US Bancorp DE 現在持有 2,270 股公司股票，價值 56,000 美元，此前在上個季度購買了 537 股。Charles Schwab Investment Management Inc.在第一季度將其在 Pacira BioSciences 的股份增加了 4.4%。Charles Schwab Investment Management Inc.現在持有 524,486 股公司股票，價值 13,033,000 美元，此前在該期間購買了 22,282 股。Connor Clark &amp; Lunn Investment Management Ltd.在第一季度將其在 Pacira BioSciences 的股份增加了 288.3%。Connor Clark &amp; Lunn Investment Management Ltd.現在持有 171,377 股公司股票，價值 4,259,000 美元，此前在上個季度購買了 127,240 股。最後，Invesco Ltd.在第一季度將其在 Pacira BioSciences 的股份增加了 159.9%。Invesco Ltd.現在持有 624,865 股公司股票，價值 15,528,000 美元，此前在上個季度購買了 384,419 股。目前 99.73% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>PCRX has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $38.00 price objective on shares of Pacira BioSciences in a research report on Monday, November 17th. Zacks Research upgraded shares of Pacira BioSciences from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, August 14th. Wall Street Zen raised shares of Pacira BioSciences from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, November 8th. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Pacira BioSciences in a report on Monday. Finally, Truist Financial decreased their price objective on Pacira BioSciences from $30.00 to $28.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 7th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $28.20.</p>
<div class="lb-trans"><p>PCRX 成為多份研究分析師報告的主題。HC Wainwright 在 11 月 17 日（星期一）的研究報告中重申了對 Pacira BioSciences 的 “買入” 評級，並設定了 38.00 美元的目標價。Zacks Research 在 8 月 14 日（星期四）的研究報告中將 Pacira BioSciences 的評級從 “強烈賣出” 上調至 “持有”。Wall Street Zen 在 11 月 8 日（星期六）的報告中將 Pacira BioSciences 的評級從 “買入” 上調至 “強烈買入”。Weiss Ratings 在週一的報告中重申了對 Pacira BioSciences 的 “賣出（d+）” 評級。最後，Truist Financial 在 11 月 7 日（星期五）的報告中將 Pacira BioSciences 的目標價從 30.00 美元下調至 28.00 美元，並對該公司設定了 “買入” 評級。三位研究分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，共識目標價為 28.20 美元。</p>
</div><p><strong>View Our Latest Stock Report on Pacira BioSciences</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Pacira BioSciences 股票報告</strong></p>
</div><h2>Pacira BioSciences Company Profile</h2>
<div class="lb-trans"><h2>Pacira BioSciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.</p>
<div class="lb-trans"><p>Pacira Biosciences, Inc.是一家控股公司，專注於提供非阿片類疼痛管理和再生健康解決方案，以改善患者在神經疼痛路徑上的體驗。其產品包括 EXPAREL、iovera 和 DepoFoam。該公司成立於 2006 年 12 月，總部位於佛羅里達州坦帕。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Pacira BioSciences</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Trading Halts Explained</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Pacira BioSciences 更好</li>
<li>如何捕捉股息增加的好處</li>
<li>2026 年應避免的 3 只最近被下調評級的股票</li>
<li>異常交易量的股票：如何實時找到異常交易量的股票</li>
<li>芯片熱潮迴歸：3 只有巨大收益潛力的股票</li>
<li>交易暫停的解釋</li>
<li>甲骨文股票受重創：為何其 AI 管道可能推動 2026 年反彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=PCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pacira BioSciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Pacira BioSciences 嗎？</h2>
</div><p>Before you consider Pacira BioSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Pacira BioSciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Pacira BioSciences 並不在名單上。</p>
</div><p>While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Pacira BioSciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

內部人士出售：Pacira BioSciences（NASDAQ:PCRX）的首席財務官出售了 9,104 股股票